A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. - Wikidata - wikimedia - TriplyDB

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

http://www.wikidata.org/entity/Q37937344

about

Optimizing treatments for lymphangioleiomyomatosis Adolescent form of sporadic lymphangioleiomyomatosis (S-LAM).Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM)Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells.Update in diffuse parenchymal lung disease 2012.Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice.

P2860

Q26865250-B40E4A9C-8F3F-4EFC-B135-B839D3BCCA87 Q34429336-678E490C-99E6-4C51-BB93-0E8CCC96A564 Q35140982-8D480403-0432-49ED-AA0F-61C3E0FB222B Q36462100-9D8ABB00-4145-4B5E-909C-F4D66B21E956 Q36636671-A0D41182-D1FC-4A49-B42A-E06E5E442793 Q37047634-4387CF28-4D3A-4FAB-B849-C5D8F4F7577E Q38103298-B462654A-D43E-46E8-8442-293273F36868 Q43182213-E8A021B1-840C-46E2-9270-5B3DB9D46566 Q48954516-E20B50DF-45B9-4E96-B18B-29B7857D1AD6

P2860

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

http://www.wikidata.org/entity/Q37937344

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

A current viewpoint of lymphan ...... therapeutic treatment options.

@en

A current viewpoint of lymphan ...... therapeutic treatment options.

@nl

type

label

A current viewpoint of lymphan ...... therapeutic treatment options.

@en

A current viewpoint of lymphan ...... therapeutic treatment options.

@nl

prefLabel

A current viewpoint of lymphan ...... therapeutic treatment options.

@en

A current viewpoint of lymphan ...... therapeutic treatment options.

@nl

P1433

Q37937344-05550F8A-F626-44E8-AF6D-5F5A4A7E6877

P1476

Q37937344-EE7A2CD4-6474-4761-92F9-300BCDD9DB27

P2093

Q37937344-668692E2-C647-4B13-AA07-22D8E54F1815

Q37937344-89A0653F-4E7D-42B1-B1EC-BC77F6D3AD76

Q37937344-E46F8764-6D8E-4313-9C53-A50881D6A6C4

Q37937344-E56EFB49-B8C9-4459-9588-044E8FAC05C3

P2860

Q37937344-00BBC7F3-D4FD-48BD-B4C8-5BD346D32C47

Q37937344-0196F53E-B1FE-4FB5-8D5C-6284B455602A

Q37937344-01F9FE3E-7059-478A-8571-3C088E9D5615

Q37937344-08CFB2C1-6857-4ED6-BD10-7CFE16B90604

Q37937344-093E31F1-4894-41AD-A779-BC70B46B58AC

Q37937344-0DD8C013-987B-4983-966D-4F0D045AE45A

Q37937344-144C5EE5-0D7C-4EAF-9F79-4BA428524D3B

Q37937344-1608DBA6-8F62-42F1-8E4A-30AA0BA673A8

Q37937344-1BFD488C-7328-4E0B-BAF1-AE993CDA8EEF

Q37937344-1F5AA496-5C9C-4E9D-B445-0D7B5677212D

P304

Q37937344-D77EF909-0FDA-44A3-8878-C057159F6510

P31

Q37937344-1A3D4ECF-A25C-4977-B292-B93EBD284543

P356

Q37937344-ABB096BB-8A2C-41B5-92D1-C9DC05208608

P433

Q37937344-851D99A8-DCA6-43EC-8861-971EC262F6AD

P478

Q37937344-63FAEBBA-E712-4D51-842D-E50FEE38A46C

P50

Q37937344-23AE3D8B-466F-4A63-86B1-66736A64487C

Q37937344-53C7855E-0D1B-48DD-8237-CEEDED64B954

P577

Q37937344-2B1B6815-043D-4664-8967-1237C565B63C

P5875

Q37937344-F75CCA8B-DB2D-4948-BC76-2BAD67B25FCB

P698

Q37937344-F83371DC-BB22-421B-837C-DCBA7DBD8340

P921

Q37937344-874392CA-AB0A-4D77-B414-04AFA9E4C822

P356

RCMB.2011-0215TR

P1433

American Journal of Respiratory Cell and Molecular Biology

P1476

A current viewpoint of lymphan ...... otherapeutic treatment options

@en

P2093

Emily R Gilbert

http://www.w3.org/2001/XMLSchema#string

I Caroline Le Poole

http://www.w3.org/2001/XMLSchema#string

Maria M Picken

http://www.w3.org/2001/XMLSchema#string

Robert B Love

http://www.w3.org/2001/XMLSchema#string

P2860

The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination

Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products

Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma

MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

P304

1-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1165/RCMB.2011-0215TR

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Daniel F Dilling

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51664319

http://www.w3.org/2001/XMLSchema#string

P698

21940815

http://www.w3.org/2001/XMLSchema#string

P921